Mergers & Acquisitions has named 11 deals as its 2024 Middle-Market Deals of the Year. Tech24 was named an Honorable Mention.

These exceptional transactions transcended a variety of market headwinds faced by dealmakers in the last year.

This marks our 17th annual Mid-Market M&A Awards. Here are this year’s winners, listed in alphabetical order and with links to full coverage. An additional 14 deals received honorable mentions. They are also listed below.

Authentic Restaurant Brands‘ take-private acquisition of Fiesta Restaurant Group was its largest acquisition to date.

The merger of Banyan Acquisition Corp. (NYSE: BYN), a publicly traded special purpose acquisition company, and Pinstripes Inc. resulted in an IPO.

Elf Beauty (NYSE: ELF)‘s acquisition of skincare brand Naturium is its largest so far.

Fanatics acquired PointsBet USA from Australian sports betting company Pointsbet Holdings after beating out competitor DraftKings (Nasdaq: DKNG) in a bidding war.

In a market where SaaS M&A activity has been down, LiveRamp Holdings (NYSE: RAMP)’s acquisition of startup Habu reflected its willingness to fund a significant inorganic expansion opportunity.

Lumentum Holdings (Nasdaq: LITE)’s acquisition of Hong Kong-based Cloud Light Technology involved a complex cross-border transaction.

Masonite International Corp. (NYSE: DOOR)’s acquisition of Fleetwood Aluminum Products broadened its product lineup and allowed it to enter new markets.

Mavis Tire Express Services Corp.’s acquisition of TBC Corporation’s retail tire business solidified its position as the largest independent tire retail dealership in North America.

In a deal that set a high benchmark for upfront consideration for the sale of a private, pre-clinical stage, biopharma company, Swiss pharmaceutical giant Novartis (NYSE: NVS) acquired DTx Pharma for $500 million in cash, plus an additional $500 million if certain milestones are met.

Canadian fintech company Nuvei Corp. (Nasdaq: NVEI)’s acquisition of payments company Paya Holdings from PE firm GTCR gave it a sizeable foothold in the United States.

Thermo Fisher Scientific (NYSE: TMO)’s acquisition of CorEvitas from Audax Private Equity complements its clinical research business.